AEMD READ THE FULL AEMD RESEARCH REPORT Cohort 2 recruitment has begun following positive data from Cohort 1 Aethlon Medical (NASDAQ:AEMD) announced FY 2Q (quarter ended September 30, 2025) results ...
Work has been completed on two treatment area improvements, both funded by charity Rosemere Cancer Foundation, which will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback